PROVIDING
ANSWERS FOR
CANCER PATIENTS

Q2

Interim report
January – June 2021

curasight

www.curasight.com

In this document, the following definitions shall apply unless otherwise specified: "the Company" or "Curasight" refers to Curasight A/S, CVR no. 35249389.

TABLE OF CONTENTS



Key figures and selected posts

Q2 (2021-04-01 – 2021-06-30)

- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -404,869 (-152,386) DKK
- Profit/loss before taxes amounted to -1,079,213 (-315,299) DKK
- Profit/loss for the year amounted to -841,783 (-245,919) DKK
- Total assets amounted to 60,860,495 (22,186,681) DKK
- Equity ratio amounted to 94.4 (79.2)
- Earnings per share amounted to -0.05 (-0.02)

Q1-Q2 (2021-01-01 – 2021-06-30)

- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -771,962 (-186,810) DKK
- Profit/loss before taxes amounted to -2,076,728 (-563,364) DKK
- Profit/loss for the year amounted to -1,619,848 (-439,424) DKK
- Total assets amounted to 60,860,495 (22,186,681) DKK
- Equity ratio amounted to 94.4 (79.2)
- Earnings per share amounted to -0.09 (-0.03)

Numbers in parenthesis are the numbers from the same period in 2020.

Definitions:
Equity ratio: Shareholders equity as a proportion of total assets.
Earnings per share: Profit/Loss for the period divided by average number of shares.

CEO Ulrich Krasilnikoff comments

Curasight awarded best IPO 2020

With great pride, we received the award, best IPO 2020, from the independent IPO Guide in Sweden. Curasight was awarded two awards, one for excellent stock price development since the IPO and the second in the quality category. Sweden is one of the most competitive IPO markets in Europe, and this award marks the quality of Curasight, its novel uPAR Theranostics technology and our team's hard efforts.

During the quarter, we reported positive outcome of the biodistribution study in Glioblastoma with uTREAT®. The preclinical study was initiated in Q4 2020 and the first step in testing new targeted radionuclides is the study of biodistribution, where both the binding to the implanted human glioblastoma tumors as well as distribution to organs are tested. The binding to the tumor needs to be sufficiently high to make a therapeutic response likely, and the biodistribution to organs needs to be such that severe side effects are unlikely. uTREAT® has now been tested in a human xenograft glioblastoma tumor model and passed both criteria, which is encouraging and constitutes a "green light" to proceed into further development and efficacy testing.

The purpose of the preclinical study in Glioblastoma is based on the promising results obtained using the diagnostic platform uTRACE® to diagnose brain cancer. A high uptake of uTRACE® in many brain tumors indicates that using PRRT (Peptide Receptor Radionuclide Therapy) in these tumors could be highly effective (the same binding moiety on uTRACE® and the PRRT). Compared with the fact that the Glioblastoma currently has a very poor prognosis with a median survival of only 14 months and five-year survival of only 5%. Despite intensive treatment efforts, including surgical resection, external radiation therapy, and chemotherapy. Therefore, we are confident that the Company may significantly improve the treatment and thus the survival rate of these patients where little improvement in the treatment has been seen over the last decade.

Glioblastoma is the first indication for uTREAT®, but uTREAT® also has potential in several other cancer types expressing the biomarker uPAR. Almost all patients with Glioblastoma express uPAR. A total of approx. 65,000 patients are diagnosed with primary brain tumors, and more than 30,000 patients are diagnosed with the aggressive form, Glioblastoma, annually in the US and EU. Approximately 10 % of the patients are children.

Curasight's uTREAT®-technology has previously shown promising results in completed preclinical studies in prostate and colorectal cancer. When complete data from the ongoing preclinical study is available, they will serve as the first proof that our therapeutic technology is working. We look forward to continuing the study and reporting its results on a continious basis.

Due to the very encouraging results from the finalised clinical phase-II study in Prostate Cancer, Curasight will look into how to accelerate the product development and testing within Prostate Cancer, as we follow the plan but at a lower cost level than first anticipated. This means that Curasight is looking into how to further unfold the vast potential of uTRACE® for diagnosing and uTREAT®-targeting radionuclide therapy in other cancer types where uPAR is also expressed.

Curasight strengthened the Board, during the quarter, with Kirsten Drejer as a new member. Her vast experience in drug development within oncology, her knowledge of building biotech companies, and her success in raising capital and closing partnership deals will greatly value Curasight going forward.

Ulrich Krasilnikoff, CEO
Curasight A/S

"During the quarter we successfully reported positive outcome of the biodistribution study in glioblastoma with uTREAT®,which constitutes a green light to proceed into further efficacy testing".

Highlights

During the second quarter

On April 9, Curasight's CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær presented the Company and its future plans, at the Nordnet Live platform.

On May 4, Curasight announced that Dr. Kirsten Drejer is to be elected as new board member in Curasight.

On May 17, Curasight is awarded Best IPO in 2020 by the independent IPO Guide.

On June 1, Curasight held an Extraordinary General Meeting where Dr. Kirsten Drejer was elected as new member of the board of directors.

On June 18, Curasight announced that SEB will initiate commissioned research, meaning that SEB will continuously monitor and analyze Curasight's operations, products, markets, and competitors.

On June 24. Curasight reported positive biodistribution data of uTREAT® in glioblastoma, which provides "green light" to proceed with the next steps of development and testing.

Q2

Best IPO 2020

On 17 May 2021 Affärsvärlden's IPO Guide announced that Curasight is awarded two prizes. The first for an excellent stock price development since the IPO and the second in the quality category. Affärsvärlden's IPO Guide examines all Swedish stock exchange listings. In 2020, 47 companies were listed on the stock exchange. Among the 7 small-cap companies Curasight's stock price development stands out as excellent with an increase 110% above that of the OMXS30 index. In the quality category the jury awarded Curasight a honorable quality award as the Company only received one flag by the IPO guide's reviewers compared to an average of 2.3 flags.

Affärsvärlden's IPO Guide applies a rigorous pre-IPO and post-IPO analysis identifying critical issues (24 predefined flags) with the aim of contributing to the quality of the IPO sector in Sweden. The awards are given in two categories. The first is Share Price Development, measured as the price development from initial subscription price onwards. It compares the relative price performance to the OMXS30, with a breakpoint 12 months after listing. As a measure, it is designed to be objective and simple. The second is Quality, which is more subjective as it relies on a jury that selects winners based on an overall assessment of three factors: 1) the lowest number of "flags" given in the pre- and post IPO analysis, 2) the share price development during the year, and 3) the jury's review.

Of the 7 small-cap companies analyzed by Affärsvärlden's IPO Guide, 2.3 flags were identified on average, compared to only 1 flag for Curasight – given for long timeline between ended subscription of units to first day of trading. Curasight's share price increased with 110% from its IPO. This refers to relative price development compared with OMXS30.

SEB initiates research

SEB has initiated its commissioned research, starting the 18 of June 2021, meaning that SEB will continuously monitor and analyze Curasight's operations, products, markets, and competitors.



Corporate Research

Curasight

SEB

NOT TO BE DISTRIBUTED IN, OR TAKEN OR TRANSMITTED INTO, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR IN ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL

Company Update | Healthcare | Denmark | 18 June 2021

Trace it, treat it

Curasight is a Danish biotech company with two core radiopharmaceutical products. The uTRACE® is for cancer diagnostics and the uTREAT® is for treatment of cancer. Due to R&D progress within nuclear medicine, interest in the radiopharmaceuticals space has skyrocketed recently. M&A activity in the field has increased and radiotherapy was a hot topic at the recent ASCO meeting. Curasight is on track to reap the benefits of this emerging trend.

Curasight is an innovator in the area of radionucleotide treatment of cancer

While we have identified several novel approaches for radionucleotide treatment of cancer we have not found any companies with a focus on uPAR. This puts Curasight in a unique position should the company's R&D activities continue to bear fruit. The pharmaceutical industry seems to be increasingly investing into radionucleotide therapies and this is a long-term positive trend for Curasight.

Investor appetite and deal activity is increasing rapidly

Despite some appealing clinical data, the market for targeted radiotherapy has never turned into a commercially attractive market. The two agents Xofigo and Lutathera constitute most commercial sales with USD 319m and USD 445m in 2020 sales respectively. However, it seems the market is at a tipping point and Big Pharma has upped its game in this field. Novartis is a great example, having invested USD óbn in radiotherapy M&A since 2018. We expect more deal-making in the space as the need for targeted therapies continues to increase.

Valuation range of DKK 30-80 per share

Curasight is an early stage biotech company and this prompts a wide valuation range. The uTREAT franchise is the most valuable franchise long-term. It does, however, also have a higher risk profile than the uTRACE franchise, which holds back the valuation. Our analysis shows that the value of Curasight can increase significantly on the back of clinical success. Our valuation range is DKK 30-80 per share with a weighted mid-point SOTP value of DKK 51 per share.

Key Data (2021E)

Price (DKK)	26.50
Reuters	CURAS.DK
Bloomberg	0
Market cap (DKKm)	528
Market cap (USDm)	85
Market cap (EURm)	71
Net debt (DKKm)	(60)
Net gearing	(72%)
Net debt/EBITDA (x)	2.3
Shares fully dil. (m)	19.9
Avg daily turnover (m)	0.0
Free float	0%

Share Price (12M)

Absolute (green) | Relative to Denmark (purple)

Marketing communication commissioned by: Curasight

Financials (DKK)

Year end: Dec	2020	2021E	2022E	2023E
Revenues (m)	0	0	0	0
Adj. EBIT	(6)	(27)	(35)	(35)
Pre-tax profit (m)	(6)	(27)	(35)	(35)
EPS	(0.32)	(1.49)	(1.76)	(1.76)
Adj. EPS	(0.32)	(1.49)	(1.76)	(1.76)
DPS	0.00	0.00	0.00	0.00
Revenue growth (%)	n.m.	n.m.	n.m.	n.m.
Adj. EBIT growth (%)	n.m.	n.m.	n.m.	n.m.
Adj. EPS growth (%)	n.m.	n.m.	n.m.	n.m.
Adj. EBIT margin (%)	n.m.	n.m.	n.m.	n.m.
ROE (%)	(14.4)	(37.4)	(53.9)	n.m.
ROCE (%)	(14.8)	(37.4)	(53.9)	n.m.
PER (x)	n.m.	n.m.	n.m.	n.m.
Free cash flow yield (%)	(2.5)	(5.6)	(6.6)	(6.6)
Dividend yield (%)	0.0	0.0	0.0	0.0
P/BV (x)	7.81	6.40	11.13	42.55
EV/Sales (x)	0.00	0.00	0.00	0.00
EV/Adj. EBITDA (x)	0.0	0.0	0.0	0.0
EV/Adj. EBIT (x)	0.0	0.0	0.0	0.0
Operating cash flow/EV (%)	n.a.	n.a.	n.a.	n.a.
Net debt/EBITDA (x)	6.44	2.25	0.70	(0.30)

Source for all data on this page: SEB (estimates) and Millistream/Thomson Reuters (prices)

research.sebgroup.com/corporate **Important**. All disclosure information can be found on pages 58 – 60 of this document

Curasight A/S in short

Curasight is a clinical phase II company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting the Positron Emissions Tomography (PET) imaging platform targeting the receptor uPAR, which is a known biomarker of cancer aggressiveness, to be used for improved diagnosis in multiple types of cancer.

PET-imaging, usually combined with CT as PET/CT, is used to create images in which the biology of the disease can be studied. The principle is that a radiolabelled tracer is injected and bound to the tissues, e.g. in a tumor, after which the radioactivity can be located with the help of a PET-scanner. Together with his team, Professor Andreas Kjaer, developed a platform based on the radiolabelled PET-tracer uTRACE®, Curasight's novel product that highlights the cancer biomarker uPAR. By injecting the patient with uTRACE®, one can both image where the cancer is located and its level of aggressiveness.

uTRACE® is imaging invasion and formation of cancer metastases (breaking down the normal tissue around the tumour). By imaging this, Curasight's technology can diagnose and determine which therapeutic strategy should be pursued, e.g. if the patient needs surgery or not. In addition, uTRACE® will be used for theranostics (principle of combined therapy and diagnostics) and precision medicine, selecting the right therapy to the right person at the right time, creating substantial benefits for both patients and the healthcare system.

Curasight's solution is expected to have big advantages in the future evaluation of prostate cancer because it may determine whether surgery is necessary or not. Today most prostate cancer patients having prostatectomies performed are operated unnecessarily and most of these patients (up to 70 percent) experience some degree of side effects, such as impotence. With Curasight's product and diagnosis, it is the company's assessment that the degree of uncertainty will be dramaticallly reduced, and these patients can be managed according to their needs – with the necessary treatment at the right time, improving patient management and generating substantial business potential.

Curasight's technology is tested in a broad pipeline with six ongoing phase II clinical trials. According to the board's assessments, there is currently no other early-stage biotech company in the field of PET tracer development that has their technology tested in a broader portfolio of clinical trials in humans (Investigator-initiated and academically sponsored), in many different cancer indications. In 2017 a phase I/IIa first-in-humans clinical trial with uTRACE® was completed. In 2018 and 2020 phase IIb clinical trials with uTRACE® in breast and prostate cancer were completed, respectively.

Moving into targeted radionuclide therapy (theranostics) – the radiation therapy of the future. With the promising results obtained within diagnostics Curasight now also pursues uPAR targeted radionuclide therapy using the uTRACE® ligand but "armed" with short-range (1 mm) radiation therapy. In brief, the therapeutic ligand will be injected into a vein after which it will circulate and bind to all cancer cells in the body (expressing uPAR) and locally irradiatecancer with limited irradiation of healthy tissue. This concept represents a more gentle form of radiotherapy compared to traditional external radiation therapy and is therefore by many is considered the "radiation therapy of tomorrow". As PET imaging and radionuclide therapy are based on the same uPAR binding peptide, a uTRACE®-scan can precisely predict where subsequent targeted radiation therapy will be delivered (theranostic principle).



Business model

Curasight aims to establish uTRACE® as the gold standard for risk stratification in prostate cancer. The geographic markets with the highest prevalence of these cancers are the U.S. and Europe. The Board and management of Curasight assess that the market potential for uTRACE® as an integral component of a new and fast-growing market for active surveillance is substantial. Importantly, as a result of the unique patient benefits and its compelling business model, Curasight expects uTRACE® to catalyse the market for active surveillance to grow it rapidly.

In brain cancer, Curasight expects its Theranostic solution uTREAT® to be game-changing and to obtain a substantial market share. The orphan (rare) disease status of this disease is expected to enable a "fast track" route to FDA approval. By establishing an advanced pipeline in multiple cancer indications, Curasight's board and management believe the Company will be an attractive candidate for partnership or out licensing agreement with Big Pharma. The area within Nuclear Molecular Imaging/Therapy has experienced strong traction with significant exit benchmarks over the recent period.

Curasight A/S in short

Outlook for Curasight

Curasight's first goal is to advance its lead products uTREAT® (used for therapy) and uTRACE® (used for diagnosing) to improve outcomes for the approx. 65,000 patients in the US and EU that are diagnosed annually with brain tumours. Accordingly, approximately 30,000 patients are diagnosed with high-grade glioma where the prognoses are very poor. Glioblastoma is a rare disease in both markets, qualifying for drug Orphan Drug Designation; moreover, because of the high unmet need, products targeting it are more likely to qualify for e.g. Priority Review, Breakthrough Therapy Designation, or Accelerated Approval.

Besides, due to the very encouraging results from the finalised clinical phase-II study in Prostate Cancer, Curasight will look into how to accelerate the product development within Prostate Cancer in order to improve the outcomes for more than half of millions new prostate cancer patients that are diagnosed annually in the US and EU.

Furthermore, Curasight is looking into how to unfold further the broadening the mission to realize the vast potential of uTRACE® for diagnosing and uTREAT® targeting radionuclide therapy in other cancer types where uPAR is also expressed.
The key milestones for 2021 are:

(i) Q3/Q4: Results from the exercise of warrants
(ii) Q4: Results from phase II clinical study in brain cancer with uTRACE®

Pipeline – multiple cancer indications

The clinical trials using Curasight's technology constitute several ongoing phase II clinical trials that address several significant unmet diagnostic and medical needs.

1) Completed; 2) Supported economically by Curasight; 3) the study has been discontinued; all Phase II studies are investigator-initiated (trial sponsor: Rigshospitalet).

Miscellaneous

Shareholders

The table below presents the management's shareholdings in Curasight

Name	Votes & capital (%)
AK 2014 Holding ApS[1]	35.11
UK Curacap ApS[2]	23.24
CHN Holding ApS[3]	14.06
Madsen Holding 2013 ApS[4]	5.31
LT 2003 ApS[5]	3.41
Per Falholt[6]	0.20
Charlotte Vedel[7]	0.04

1. Owned by co-founder, CSO, and Board Member Andreas Kjaer
2. Owned by CEO and Board Member Ulrich Krasilnikoff
3. Owned by co-founder and Director Pre-Clinical Carsten H Nielsen
4. Owned by Co-founder and Director CMC, Jacob Madsen
5. Owned by Deputy Chairman of the Board, Lars Trolle
6. Chairman of the Board
7. Board Member

The share

The shares of Curasight A/S were listed on Spotlight Stock Market on October 8, 2020.

The short name/ticker is CURAS, and the ISIN code is DK0061295797. In addition, there are a total of 2,835,000 warrants of series TO 1 issued. Each warrant of series TO 1 entitles the holder the right to subscribe for one (1) new share in Curasight at a subscription price of DKK 17.20 per share during the exercise period September 16, 2021, until October 7, 2021. Curasight's warrants of series TO 1 are traded under the ticker CURAS TO 1 with ISIN DK0061408747. As of June 30, 2021, the number of shares was 17,126,340 (13,886,340). All shares have equal rights to the Company´s assets and results.

Risks

A number of risk factors can affect Curasight's operations. It is therefore of great importance to consider relevant risks in addition to the Company's growth opportunities. For a detailed description of the risks attributable to the Company and its shares, please refer to the prospectus published by the Company in 2020. The prospectus is available on Curasight's website www.curasight.com.

Accounting policy

The financial statements have been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B as well as selected rules applying to reporting class C. This interim report has been prepared using the same accounting principles.

Auditor´s review

The interim report has not been reviewed by the Company's auditor.

Financial calendar

Q3 2021	November 25, 2021
Q4 2021	February 24, 2022
Annual Report 2021	February 24 ,2022

For further information, please contact

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com

Financial statements

Income statement

Operating profit/loss before tax for the second quarter of 2021 amounted to DKK -1,079,213 (-315,299). Operating profit/loss before tax for the first half year of 2021 amounted to DKK -2,076,728 (-563,364).

External expenses for the second quarter amounted to DKK -1,010,043 (-314,502) and staff expenses are DKK-357,760 (-147,921). External expenses for the first half year amounted to DKK -1,941,281 (-560,742) and staff expenses are DKK -653,503 (-336,892). External expenses comprise of clinical expenses, patent expenses, and business expenses.

Balance sheet

Per June 30, 2021, the Company's balance sheet amounted to DKK 60,860,495 (22,186,981). The assets consisted primarily of development projects totaling DKK 22,467,573 related to the development of uTRACE® and uTREAT®. The Company's cash amounted to DKK 34,092,041. The equity and liabilities consisted primarily of an equity totaling DKK 57,510,634.

Cash flow

Curasight's cash flow from operating activities in January–June 2021 amounted to DKK -1,063,346. This post was primarily affected by the Company's loss for the period of DKK -841,783.

Cash as of June 30, 2021, is DKK 34,092,041 (538,115).

Income statement

(DKK)	2021 Q2*	2020 Q2*	2021 Q1-Q2*	2020 Q1-Q2*	2020
Gross profit/loss	**-404,869**	**-152,386**	**-771,962**	**-186,810**	**-4,791,150**
Staff expenses	-357,760	-147,921	-653,503	-336,892	-844,421
Depreciation, amortisation and impairment of intangible assets and property, plant and equipment	-247,414	-14,195	-515,816	-37,040	-73,607
Profit/loss before financial income and expenses	**-1,010,043**	**-314,502**	**-1,941,281**	**-560,742**	**-5,709,178**
Financial costs	-69,170	-797	-135,447	-2,622	-64,397
Profit/loss before tax	**-1,079,213**	**-315,299**	**-2,076,728**	**-563,364**	**-5,773,575**
Tax on profit/loss for the year	237,430	69,380	456,880	123,940	221,374
Net profit/loss for the year	**-841,783**	**-245,919**	**-1,619,848**	**-439,424**	**-5,552,201**

*) Unaudited figures

Balance sheet - Assets

(DKK)	2021 Q1-Q2*	2020 Q1-Q2*	2020
Acquired patents	2,971,573	484,224	3,467,522
Development projects in progress	22,467,573	20,666,214	21,669,573
Intangible assets	**25,439,146**	**21,150,438**	**25,137,095**
Other fixtures and fittings, tools and equipment	198,684	238,416	218,550
Property, plant and equipment	**198,684**	**238,416**	**218,550**
Fixed assets	**25,637,830**	**21,388,854**	**25,355,645**
Other receivables	256,840	135,791	1,112,929
Corporation tax	873,784	124,221	353,019
Receivables	**1,130,624**	**260,012**	**1,465,948**
Cash at bank and in hand	**34,092,041**	**538,115**	**36,284,252**
Currents assets	**35,222,665**	**798,127**	**37,750,200**
Assets	**60,860,495**	**22,186,681**	**63,105,845**

*) Unaudited figures

Balance sheet - Liabilities and equity

(DKK)	2021 Q1-Q2*	2020 Q1-Q2*	2020
Share capital	856,317	694,317	856,317
Reserve for development costs	19,429,935	16,642,737	18,631,935
Retained earnings	37,224,382	250,205	39,642,230
Equity	**57,510,634**	**17,587,259**	**59,130,482**
Provision for deferred tax	1,953,587	1,822,222	1,953,587
Provisions	**1,953,587**	**1,822,222**	**1,953,587**
Trade payables	1,895	1,250,000	359,786
Deferred income	1,082,417	1,010,269	1,082,417
Other payables	311,962	517,231	579,573
Short-term debt	**1,396,274**	**2,777,500**	**2,021,776**
Debt	**1,396,274**	**2,777,500**	**2,021,776**
Liabilities and equity	**60,860,495**	**22,186,981**	**63,105,845**

*) Unaudited figures

Equity - Q2 2021

(DKK) Change in Equity: Q1-2021*	Share capital	Reserve for development costs	Retained earnings	Total
Equity at 1 April 2021	**856,317**	**19,030,935**	**38,465,165**	**58,352,417**
Development costs for the year	0	399,000	-399,000	0
Net profit/loss for the period	0	0	-841,783	-841,783
Equity at 30 June 2021	**856,317**	**19,429,935**	**37,224,382**	**57,510,634**

Equity - Q2 2020

(DKK) Change in Equity: Q1-2020*	Share capital	Reserve for development costs	Retained earnings	Total
Equity at 1 April 2020	**694,317**	**16,342,737**	**796,124**	**17,833,178**
Development costs for the year	0	300,000	-300,000	0
Net profit/loss for the period	0	0	-245,919	-245,919
Equity at 30 June 2020	**694,317**	**16,642,737**	**250,205**	**17,587,259**

Equity - Q1-Q2 2021

(DKK) Change in Equity: Q1-Q2 2021*	Share capital	Reserve for development costs	Retained earnings	Total
Equity at 1 January 2020	**856,317**	**18,631,935**	**39,642,230**	**59,130,482**
Development costs for the year	0	798,000	-798,000	0
Net profit/loss for the period	0	0	-1,619,848	-1,619,848
Equity at 30 June 2020	**856,317**	**19,429,935**	**37,224,382**	**57,510,634**

Equity - Q1-Q2 2020

(DKK) Change in Equity: Q1-Q2 2020*	Share capital	Reserve for development costs	Retained earnings	Total
Equity at 1 January 2020	**694,317**	**16,042,737**	**1,289,629**	**18,026,683**
Development costs for the period	0	600,000	-600,000	0
Net profit/loss for the period	0	0	-439,424	-439,424
Equity at 30 June 2020	**694,317**	**16,642,737**	**250,205**	**17,587,259**

*) Unaudited figures

Equity - 2020

(DKK)	Share capital	Share Premium Account	Reserve for development costs	Retained earnings	Total
Equity at 1 January 2020	**694,317**	**0**	**16,042,737**	**1,289,629**	**18,026,683**
Cash capital increase	162,000	46,494,000	0	0	46,656,000
Development costs for the year	0	0	2,589,198	-2,589,198	0
Net profit/loss for the period	0	0	0	-5,552,201	-5,552,201
Transfer from share premium account	0	-46,494,000	0	46,494,000	0
Equity at 31 December 2020	**856,317**	**0**	**18,631,935**	**39,642,230**	**59,130,482**

Cash flow statement

(DKK)	2021 Q2*	2020 Q2*	2021 Q1-Q2*	2020 Q1-Q2*	2020
Net profit/loss for the year	-841,783	-245,919	-1,619,848	-439,424	-5,552,201
Adjustments	-56,293	17,761	58,936	-12,129	-83,370
Change in working capital	-165,270	20,585	366,033	76,247	-1,584,465
Cash flow from operating activities before financial income and expenses	**-1,063,346**	**-207,573**	**-1,194,879**	**-375,306**	**-7,220,036**
Financial expenses	-69,170	-797	-135,447	-2,622	-64,396
Cash flow from ordinary activities	**-1,132,516**	**-208,370**	**-1,330,326**	**-377,928**	**-7,284,432**
Corporation tax received	0	321,025	-63,885	321,025	321,025
Cash flows from operating activities	**-1,132,516**	**112,665**	**-1,394,211**	**-56,903**	**-6,963,407**
Purchase of intangible assets	-399,000	-300,000	-798,000	-600,000	**-4,603,359**
Cash flow from investing activities	**-399,000**	**-300,000**	**-798,000**	**-600,000**	**-4,603,359**
Cash capital increase	0	0	0	0	46,656,000
Development costs	0	0	0	0	0
Dividend	0	0	0	0	0
Cash flow from financing activities	**0**	**0**	**0**	**0**	**46,656,000**
Total cash flow from the period	**-1,531,516**	**-187,345**	**-2,192,211**	**-656,903**	**35,089,234**
Cash, beginning of the period	35,623,557	725,460	36,284,252	1,195,018	1,195,018
Cash, end of the period	**34,092,041**	**538,115**	**34,092,041**	**538,115**	**36,284,252**

*) Unaudited figures

Statement by the Board of Directors

The Board of Directors provide their assurance that the interim report provides a fair and true overview of the Company's operations, financial position, and results.

København N, 24 August 2021

Executive Board
Ulrich Krasilnikoff, CEO

Board of Directors
Per Falholt, Chairman
Lars Trolle
Charlotte Vedel
Ulrich Krasilnikoff
Andreas Kjær

Contact information
Curasight A/S
Ole Maaløes Vej 3
2200 Copenhagen
Denmark
Email: info@curasight.com
Phone: + 4522830160